Just released @Health_Affairs ... Yale/Harvard study of how well COVID-19 vaccines will work and what will affect this. Solid research with important messages. Hope
@MoH_SriLanka @sudathsamara #COVIDvaccine team will look at it. healthaffairs.org/doi/10.1377/hl…
1/5
@MoH_SriLanka @sudathsamara #COVIDvaccine team will look at it. healthaffairs.org/doi/10.1377/hl…
1/5
KEY TAKEAWAYS
1. Vaccines are not the same. Must differentiate according to: #1 how well they reduce illness in infected persons; and #2 how much they prevent infection.
*Pfizer vaccine likely 90% good at reducing illness, but only 50% good at preventing infection.
2/5
1. Vaccines are not the same. Must differentiate according to: #1 how well they reduce illness in infected persons; and #2 how much they prevent infection.
*Pfizer vaccine likely 90% good at reducing illness, but only 50% good at preventing infection.
2/5
2. Vaccinating most of the population rapidly with a highly effective 1st generation vaccine like Pfizers is not enough to get to zero cases and deaths.
3/5
3/5
3. Vaccine effectiveness depends critically on how well other interventions are controlling spread. If these are weak, vaccine effectiveness is low, and logically cost-effectiveness too.
4/5
4/5
BOTTOM LINE
We still need to invest in scaling up #PCR capacity to mop up cases after vaccine without lockdowns, and most importantly to maximize cost-effectiveness of a vaccine. If we don't, vaccines could prove to be money down the drain.
5/5
We still need to invest in scaling up #PCR capacity to mop up cases after vaccine without lockdowns, and most importantly to maximize cost-effectiveness of a vaccine. If we don't, vaccines could prove to be money down the drain.
5/5
• • •
Missing some Tweet in this thread? You can try to
force a refresh
